These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25394055)

  • 1. Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viraemia.
    Viskovic K; Zidovec-Lepej S; Gorenec L; Grgic I; Lukas D; Zekan S; Dragobratovic A; Begovac J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19548. PubMed ID: 25394055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia.
    Višković K; Židovec Lepej S; Gorenec A; Grgić I; Lukas D; Zekan Š; Dragobratović A; Trupković M; Begovac J
    Sci Rep; 2018 Apr; 8(1):6113. PubMed ID: 29666424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study.
    Olmo M; Saumoy M; Alonso-Villaverde C; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Curto J; Domingo P; Oteo JA; Vila A; Podzamczer D
    HIV Med; 2012 Sep; 13(8):488-98. PubMed ID: 22416676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
    Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment.
    Bernal E; Serrano J; Perez A; Valero S; Garcia E; Marín I; Muñoz A; Verdú JM; Vera C; Cano A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19723. PubMed ID: 25397469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
    Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; Genebat M; Vera F; Benhnia MR; Bravo-Urbieta J; Galera-Peñaranda C; de Pablo-Bernal RS; Abad-Carrillo MA; Leal M; Ruiz-Mateos E;
    Antiviral Res; 2014 Nov; 111():26-32. PubMed ID: 25173576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc.
    Bernal E; Verdú JM; Vera F; Martinez O; Bravo J; Galera C; Muñoz A; Garcia E; Serrano J; Perez A; Vera C; Marín I; Cano A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19726. PubMed ID: 25397472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
    Seang S; Fourati S; Keita Y; Blanc C; Tubiana R; Schneider L; Valantin MA; Caby F; Calin R; Lambert-Niclot S; Marcelin AG; Calvez V; Costagliola D; Katlama C
    J Antimicrob Chemother; 2014 Dec; 69(12):3356-9. PubMed ID: 25056835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
    Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
    AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.
    Levy AR; McCandless L; Harrigan PR; Hogg RS; Bondy G; Iloeje UH; Mukherjee J; Montaner JS
    Lipids Health Dis; 2005 Feb; 4():4. PubMed ID: 15705191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study.
    Kim JY; Zaoutis T; Chu J; Zhao H; Rutstein R
    Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):589-94. PubMed ID: 19402031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epi-aortic lesions, pathologic FMD, endothelial activation and inflammatory markers in advanced naïve HIV-infected patients starting ART therapy.
    Bellacosa C; Maggi P; Volpe A; Altizio S; Ladisa N; Cicalini S; Viglietti R; Chirianni A; Bellazzi L; Zanaboni D; Maserati R; Martinelli C; Corsi P; Sofia S; Celesia M; Sozio F; Abbrescia N; Angarano G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19545. PubMed ID: 25394052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.